Syncope is a challenging presentation because it can represent multiple underlying conditions. Concern for a cause that may result in serious morbidity and mortality often results in a hospital admission.[@bib1] Although hospitalization allows for cardiac monitoring and expedites testing and specialist evaluation, anywhere from one-third to one-half of all patients have unexplained syncope at discharge.[@bib2]^,^[@bib3]

Several small single-center studies have reported on the high costs associated with a hospital evaluation for syncope.[@bib4], [@bib5], [@bib6] When the mean cost of admission was converted to US dollars to allow for comparison, those estimates ranged from \$1700 in the United Kingdom[@bib4] to \$16,000 in Spain.[@bib6] A single study from approximately 20 years ago conducted in the United States provides the only national estimate for the overall annual hospitalization cost burden of syncope, estimated at \$2.4 billion (US) dollars.[@bib7]

Compared with other countries, admission rates in Canada are significantly lower (12%-15%).[@bib8]^,^[@bib9] However, a study performed in Alberta found regardless of emergency department (ED) discharge status (home vs hospitalization), the largest proportion of annual costs for syncope patients was attributed to hospitalizations.[@bib8] At present, the current and future cost burden of syncope hospitalizations in Canada are unknown. Accordingly, we estimated costs of acute care hospitalizations with a primary diagnosis of syncope in Canada between 2004 and 2015 and extrapolated the future cost burden to 2030.

Methods {#sec1}
=======

Data source and study population {#sec1.1}
--------------------------------

The Canadian Institute for Health Information Discharge Abstract Database (DAD) was used to identify hospitalizations with a primary diagnosis of syncope (International Classification of Diseases \[ICD\], 10th revision, code R55) between April 2004 and March 2016 (fiscal years \[FY\] 2004-2015). The ICD-10 code R55 has been found to have a sensitivity of 62.7% and a specificity of 99.9% and used in research previously.[@bib8]^,^[@bib10], [@bib11], [@bib12], [@bib13] The DAD includes data on patient demographics, diagnoses, discharge deposition, case mix group classification (to identify homogenous patient clusters), and resource intensity weights (RIW), which indicate the level of a patient's resource consumption during a hospital stay, contingent on diagnostic case mix group.[@bib14]^,^[@bib15] The DAD contains complete hospitalization data for all Canadian provinces and territories except Quebec.[@bib15]

Main outcomes {#sec1.2}
-------------

The main outcomes were annual syncope hospitalization costs in Canada from FY2004 to 2015. Other outcomes included distribution of hospitalization costs by province, sex, and age groups (\<60, 60-69, 70-79, and ≥80 years) and projections of annual syncope hospitalization costs in Canada to FY2030.

Hospitalization costs in Canada between FY2004 and 2015 (except Quebec) {#sec1.3}
-----------------------------------------------------------------------

Hospitalization cost refers only to costs incurred after admission from the ED. We estimated the cost of a hospitalization by multiplying the RIW with the Canadian cost of a standard hospital stay (CSHS).[@bib16] The CSHS provides the average costs incurred through the direct care of a standard hospitalization (RIW = 1.00) (e.g., nursing, diagnostic, and therapeutic costs).[@bib14] The CSHS is only available from FY2011 to 2015 ([Supplementary Table S1](#appsec1){ref-type="sec"});[@bib16] therefore, we estimated the costs of a syncope hospitalization between FY2004 and 2010 as follows: First, we developed a generalized linear model (GLM) with gamma distribution and log link to calculate the average costs per syncope hospitalization for each year during FY2011 to 2015. This methodology has been reported in detail.[@bib17], [@bib18], [@bib19] In brief, the gamma distribution was selected on the basis of the Modified Park test (lambda = 2).[@bib20] The independent variables included FY and patient sex and age groups. We then applied the GLM model's coefficients to estimate average costs per hospitalization for the years for which CSHS data were not available (FY2004-2010). The costs of individual hospitalizations for each FY in each province were then summed to have annual syncope hospitalization costs for each province (except Quebec) between FY2004 and 2015.

Hospitalization costs in Quebec between FY2004 and 2015 {#sec1.4}
-------------------------------------------------------

In the absence of hospitalization data from Quebec, we assumed syncope hospitalization rates in the province to be the average hospitalization prevalence rates observed across the rest of the country for each sex and age group combination. We applied the average prevalence rates to the Quebec population to estimate the number of syncope hospitalizations each year during FY2004 to 2015.[@bib21] The annual syncope hospitalization costs in Quebec were then derived by multiplying the number of hospitalizations with average costs per hospitalization (from the GLM model described) for each FY for each specific sex and age group. This method has been used to estimate the costs of other conditions previously.[@bib22]^,^[@bib23]

The average hospitalization prevalence rates were estimated as follows. We first calculated the syncope hospitalization prevalence rates per 100,000 population for each combination group of sex and age each FY during FY2004 to 2015 for the rest of Canada and then used multiple linear regression (MLR) to estimate the average prevalence rates during this time period. The outcome variable of the MLR model was a natural logarithm of the prevalence rate, and the covariates in the model were FY, sex, and age group. We used likelihood ratio test to examine inclusion of sex/age interaction. Interaction remained in the final model if the likelihood ratio test was significant at a 5% level. Model assumptions (homoscedasticity, normality of residuals, and the linearity of relationships between the outcome and FY as a continuous predictor) were checked and explored for unusual and influential observations by examining residuals and leverage values. We summed annual hospitalization costs in each province to estimate the Canadian hospitalization costs between FY2004 and 2015.

Hospitalization costs in Canada between FY2016 and 2030 {#sec1.5}
-------------------------------------------------------

To estimate future costs, we assumed that the trends seen from FY2004 to 2015 would continue. We used the MLR and GLM models' coefficients to calculate hospitalization prevalence rates and costs per hospitalization for each sex and age group for each FY between FY2016 and 2030. The estimated prevalence rates were multiplied by the Canadian population (medium growth \[M5\] scenario) to calculate the number of syncope hospitalizations annually until FY2030.[@bib24] We multiplied the estimated number of hospitalizations by the costs per hospitalization to estimate annual syncope hospitalization costs between FY2016 and 2030 in Canada.

Sensitivity analysis {#sec1.6}
--------------------

We conducted 2 sensitivity analyses. First, we included only hospitalizations for a primary diagnosis of syncope in the main analysis. We performed another analysis in which both primary and secondary diagnosed syncope hospitalizations were included. Second, we used the medium growth scenario (M5) for projected Canadian population in the main analysis of hospitalization costs for syncope between FY 2016 and 2030.[@bib24] We conducted an additional analysis of hospitalization costs during this period using low and high growth scenarios to examine impact of population growth on hospitalization costs for syncope in Canada.

Statistical analysis {#sec1.7}
--------------------

Patient characteristics were summarized using count, percentage, mean (±standard deviation), and median (interquartile range), as appropriate, and were reported each FY during the study period. Previously validated ICD codes were used to identify patient comorbidities.[@bib25] Comorbidities in a given FY were considered to be present if they were recorded in any hospitalization during that FY. Univariate GLM regression was used for trend test of costs. All costs in this study were inflated to 2018 Canadian dollar values using Canadian Consumer Price Index.[@bib26]

All analyses were performed using Stata version 14 (Stata Corp., LP, College Station, TX). Two-sided *P* values \< 0.05 were considered statistically significant. The study was approved by the Health Research Ethics Board at the University of Alberta (Institutional Review Board Number: Pro00072777).

Results {#sec2}
=======

Baseline characteristics {#sec2.1}
------------------------

A total of 128,263 syncope hospitalizations for 116,630 unique patients occurred between FY2004 and 2015 in Canada (less Quebec). Hospitalizations for men increased (2004: 50.7%, 2015: 53.4%, *P \<* 0.001), whereas mean patient age remained unchanged (70 years, *P* = 0.26) during the study period. The most prevalent comorbidity was diabetes, and it increased over time (2004: 11.4%, 2015: 21%, *P \<* 0.001), as did the expected length of stay (2004: 2.9 days, 2015: 3.3 days, *P \<* 0.001) ([Table 1](#tbl1){ref-type="table"}). The number of syncope hospitalizations by province is presented in [Supplementary Table S2](#appsec1){ref-type="sec"}.Table 1Baseline statistics of patients with syncope hospitalized, 2004-2015 (excluding Quebec)Variable200420052006200720082009201020112012201320142015Admissions, N10,37410,23410,23310,15410,27310,35910,65410,87311,47411,50511,19510,935eLOS, mean (SD)[∗](#tbl1fnlowast){ref-type="table-fn"}2.93.33.33.33.23.23.23.23.33.43.53.3(1.6)(1.7)(1.6)(2.1)(1.8)(1.7)(1.7)(2)(2)(2)(2.4)(1.9)Male, n (%)526351405193514952695316536756485958599658915842(50.7)(50.2)(50.7)(50.7)(51.3)(51.3)(50.4)(51.9)(51.9)(52.1)(52.6)(53.4)Age, mean (SD)70.070.070.170.269.869.570.070.369.970.070.470.1(18)(18.3)(18.3)(18.4)(18.7)(18.9)(18.4)(18.5)(18.8)(18.7)(18.7)(18.7)Age group, n (%)[†](#tbl1fndagger){ref-type="table-fn"} \<60 y236523592319225323672491248125152707265824922501(22.8)(23.1)(22.7)(22.2)(23)(24)(23.3)(23.1)(23.6)(23.1)(22.3)(22.9) 60-69 y146613731379146615071529161516431771182717921727(14.1)(13.4)(13.5)(14.4)(14.7)(14.8)(15.2)(15.1)(15.4)(15.9)(16)(15.8) 70-79 y282226992640259825472511254625182655265325892595(27.2)(26.4)(25.8)(25.6)(24.8)(24.2)(23.9)(23.2)(23.1)(23.1)(23.1)(23.7) ≥80 y372138033895383738523828401241974341436743224112(35.9)(37.2)(38.1)(37.8)(37.5)(37)(37.7)(38.6)(37.8)(38)(38.6)(37.6)Selected comorbidity, n (%) Heart failure422406388386389421452452521511537451(4.1)(4)(3.8)(3.8)(3.8)(4.1)(4.2)(4.2)(4.5)(4.4)(4.8)(4.1) COPD394416416396421419504477515503501449(3.8)(4.1)(4.1)(3.9)(4.1)(4)(4.7)(4.4)(4.5)(4.4)(4.5)(4.1) Dementia430486526474489527582551596618583544(4.1)(4.7)(5.1)(4.7)(4.8)(5.1)(5.5)(5.1)(5.2)(5.4)(5.2)(5) Diabetes118512071684181919251928204321222330229723112,299(11.4)(11.8)(16.5)(17.9)(18.7)(18.6)(19.2)(19.5)(20.3)(20)(20.6)(21) Renal disease370424379391436359360363418399459497(3.6)(4.1)(3.7)(3.9)(4.2)(3.5)(3.4)(3.3)(3.6)(3.5)(4.1)(4.5)[^1][^2][^3]

Hospitalization costs in Canada (except Quebec) between FY2004 and 2015

Syncope cost the Canadian health systems (except Quebec) \$619.9 million in hospital services between FY2004 and 2015, of which Ontario accounted for the largest proportion (50.7%), followed by British Columbia (18.5%) and Alberta (9.2%). Annual hospitalization costs increased from \$51.2 million in FY2004 to a peak of \$55.7 million in FY2012, and then decreased to \$50.9 million in FY2015 ([Table 2](#tbl2){ref-type="table"}). Total hospitalization costs for male patients were higher than those for female patients, primarily due to higher prevalence rates in male patients, and hospitalization costs for the most senior group (aged ≥ 80 years) accounted for the majority in both sexes ([Table 3](#tbl3){ref-type="table"} and [Fig. 1](#fig1){ref-type="fig"}). Results of the GLM model and estimated average costs per syncope hospitalization are presented in [Supplementary Tables S3](#appsec1){ref-type="sec"} and [S4](#appsec1){ref-type="sec"}, respectively.Table 2Hospitalization costs for syncope by province in Canada (except Quebec, in million, 2018 CA\$ values), 2004-2015ProvinceAll200420052006200720082009201020112012201320142015Alberta57.14.24.94.14.24.24.44.45.36.05.25.34.9British Columbia114.68.07.88.48.59.09.39.99.311.011.311.310.8Manitoba20.61.91.91.81.71.61.51.71.61.61.91.71.9New Brunswick33.12.72.73.03.12.82.62.82.73.12.52.82.3Newfoundland and Labrador16.31.01.21.11.11.31.11.31.31.71.61.81.9Nova Scotia22.92.11.91.81.71.81.81.92.52.02.41.61.6Ontario314.427.626.426.625.825.625.926.226.526.826.525.824.7Prince Edward Island4.30.30.40.30.40.30.40.30.50.40.40.40.2Saskatchewan35.23.23.03.23.13.13.02.82.73.12.62.62.6Territories1.30.10.10.10.10.20.10.10.10.10.10.10.1Total619.951.250.450.349.750.050.051.352.655.754.453.550.9Table 3Hospitalization costs for syncope in Canada (except Quebec) between FY2004 and 2015 by sex and age (in million, 2018 \$ values)Age groupAllFemaleMale\<60 y10644.361.660-69 y81.830.751.170-79 y153.769.983.8≥80 y278.3158.5119.8Total[∗](#tbl3fnlowast){ref-type="table-fn"}619.9303.5316.4[^4]Figure 1Syncope hospitalization prevalence rates in Canada (except Quebec), 2004-2015.

Hospitalization costs in Quebec between FY2004 and 2015

Extrapolating the syncope hospitalization rates in the rest of Canada ([Fig. 1](#fig1){ref-type="fig"}) to Quebec population resulted in 41,044 hospitalizations with a primary diagnosis of syncope in Quebec between FY2004 and 2015, corresponding to a total cost of \$198.7 million during this period ([Supplementary Table S5](#appsec1){ref-type="sec"}). By adding Quebec, the annual hospitalization costs countrywide were \$66.6 million in FY2004 and increased to \$68.5 million in FY2015. The total costs of syncope hospitalization in Canada during this period were \$818.5 million ([Fig. 2](#fig2){ref-type="fig"}). Detailed results of the MLR model and estimated syncope hospitalization prevalence rates per 100,000 populations by sex and age are presented in [Supplementary Tables S6](#appsec1){ref-type="sec"} and [S7](#appsec1){ref-type="sec"}, respectively.Figure 2Syncope hospitalization costs in Canada (in million, 2018 \$ values), 2004-2030.

Hospitalization costs in Canada between FY2016 and 2030 {#sec2.2}
-------------------------------------------------------

Although rates of hospitalization decreased over time ([Fig. 1](#fig1){ref-type="fig"}, *P \<* 0.001), the absolute number of syncope hospitalizations in Canada is projected to increase from 14,620 in 2015 to 18,793 in 2030 ([Supplementary Table S8](#appsec1){ref-type="sec"}), primarily due to a composite effect of population growth and ageing. Accordingly, the hospitalization costs were projected to increase from \$68.5 million in 2015 to \$87.1 million in 2030 ([Fig. 2](#fig2){ref-type="fig"}).

Sensitivity analysis {#sec2.3}
--------------------

Including both primary and secondary diagnoses, hospitalization costs increased to \$242.9 and \$426 million in 2015 and 2030, respectively. Low and high population growths corresponded to a range of hospitalization costs for syncope as the primary diagnosis of \$84.2 to \$91.1 million in 2030.

Discussion {#sec3}
==========

This contemporary study provides the first costs estimate of syncope-related hospitalization in Canada. We estimated hospitalizations with a primary diagnosis of syncope over a 10-year period cost the Canadian health systems \$818.5 million dollars. The annual hospitalization costs have been increasing over time and are projected to increase 27% by 2030. When both primary and secondary diagnoses of syncope were considered, the hospitalization costs in Canada are expected to increase 5-fold to \$426 million in 2030.

Syncope hospital services alone accounted for 0.1% of national hospital spending in 2015.[@bib27] Even though the hospitalization cost burden is not comparable to other conditions, such as heart failure (HF) or congenital heart disease,[@bib23]^,^[@bib28] the overall cost burden of syncope in Canada is considerable given only approximately 10,000 patients with syncope are admitted annually, much less compared with patients with HF. Measures are needed to respond to the projected increasing costs of syncope. In a nationwide study, we previous demonstrated that approximately two-thirds of hospitalized patients are without any comorbidity (Charlson comorbidity score = 0).[@bib13] Strategies aimed at reducing unnecessary admissions among low-risk patients are needed. This may include community interventions (e.g., risk stratification performed by emergency medical services or establishing care pathways for urgent referrals to appropriate outpatient clinics) or interventions within the ED (e.g., a dedicated syncope management unit).[@bib29] Regardless of the intervention, research is needed to identify a cost-effective strategy that is feasible for a Canadian healthcare system.

Unlike other cardiovascular conditions, such as acute myocardial infarction, where hospitalization costs account for as much as 81% of the total healthcare cost burden,[@bib18]^,^[@bib19] outpatient services may be the driver of the cost burden for syncope. Epidemiological studies have shown that of the patients who have a syncope event and are seen in the outpatient setting, only a small fraction of syncope patients are referred to the ED.[@bib30]^,^[@bib31] Although the DAD does not provide costs beyond hospitalization, a study performed in Alberta was able to perform a comprehensive evaluation of syncope-related costs (outpatient, physician claims, and drugs) and found anywhere from 26% to 52% of costs depending on whether patients were discharged or hospitalized were nonhospital related.[@bib8] This study also found that 85% of patients presenting with a primary diagnosis of syncope to the ED are discharged, so further research is needed to quantify the costs related on this setting because these data suggest cost-saving interventions for this subgroup of patients may be an cost-effective strategy.

We found that the syncope hospitalization costs per capita in Canada (\$2 in 2005, in \$ 2018 values) were lower than in the United States (\$4.9 in 2005, converted to Canadian dollar 2018 values[@bib7]^,^[@bib32], [@bib33], [@bib34]). This may stem from differences in practice between the 2 countries. Compared with Canada, the United States has had higher rates of ED presentation and hospital admissions for syncope.[@bib8]^,^[@bib35]^,^[@bib36] In addition, the costs per a health service encounter for syncope vary significantly depending on local practice standards, types of evaluation, testing, and whether intervention is required.[@bib37] We found the hospital costs were higher for men compared with women, which is explained by sex differences in admission rates. Our prior work[@bib8]^,^[@bib13]^,^[@bib38] and others[@bib39] have found that men were more likely to be admitted than woman and admission among men had increased over time.

Limitations {#sec3.1}
-----------

Although our study provides novel data on syncope hospitalization cost burden in Canada, it has limitations. First, we assumed that the trends seen between 2004 and 2015 would continue when projecting future costs. We provided 95% confidence intervals (presented in the Supplementary Material) and low and high estimates of population growths to account for uncertainty. Second, we lacked hospitalization data from Quebec and assumed that the rate of hospitalization in Quebec would be the same as the rest of Canada. We examined variations across the provinces and found no statistically significant differences in hospitalization rates across provinces for which we have data. Third, the national database did not allow for quantifying the type/number of tests and specialist evaluations performed during hospitalization. These data may help to identify an opportunity to reduce cost. Finally, the sensitivity of 62.7% for the code R55 suggests that the true cost burden of syncope in Canada could be substantially higher.

Conclusions {#sec4}
===========

Syncope cost the Canadian healthcare system \$818.5 million in hospital services from 2004 to 2015. The annual hospitalization costs have been increasing and are projected to increase 27% by 2030. To reduce costs, further research is needed to identify strategies to deliver more efficient syncope care in acute care settings.
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[^1]: AMI, acute myocardial infarction; COPD, chronic obstructive pulmonary disease; eLOS, expected length of stay; SD, standard deviation.

[^2]: eLOS is the number of days in the hospital assigned to each admission based on Canadian Institute for Health Information grouping methodology.

[^3]: Total proportion may not be exactly 100% because of rounding.

[^4]: Total costs may not be exactly the same as the sum of its subgroups because of rounding.
